No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARCT240517C25000
- 2.45
- -1.25-33.78%
15min DelayClose May 10 16:00 ET
2.45High2.20Low
2.20Open3.70Pre Close8 Volume328 Open Interest25.00Strike Price1.81KTurnover62.16%IV0.42%PremiumMay 17, 2024Expiry Date2.26Intrinsic Value100Multiplier4DDays to Expiry0.19Time Value100Contract SizeAmericanOptions Type0.8969Delta0.0927Gamma11.48Leverage Ratio-0.0385Theta0.0029Rho10.29Eff Leverage0.0056Vega
Intraday
- 5D
- 1D
News
Arcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards Growth
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $86
Arcturus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 219.47% Canaccord Genuity $87 → $86 Maintains Buy 03/20/2024 122.88% HC Wainwright & Co. → $60
Buy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical Advancements
Earnings Call Summary | Arcturus Therapeutics(ARCT.US) Q1 2024 Earnings Conference
The following is a summary of the Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript:Financial Performance:Arcturus reported Q1 2024 revenues of $38 million, an increase from
Comments
Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.
Analysts Have Made A Financial Statement On Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Yearly ReportDespite Arcturus Therapeutics Holdings Inc.'s strong run, its P/S ratio remains low due to a weak revenue outlook. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio, forming a barrier for the share price.
The recent improvement in total shareholder return could indicate that the business is getting better over time. However, there are 2 warning signs that investors should be aware of. The sentiment around the company seems to be positive lately.
Read more